These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. Fujinaga Y; Kawaratani H; Kaya D; Tsuji Y; Ozutsumi T; Furukawa M; Kitagawa K; Sato S; Nishimura N; Sawada Y; Takaya H; Kaji K; Shimozato N; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759852 [TBL] [Abstract][Full Text] [Related]
7. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. Namisaki T; Kaji K; Shimozato N; Kaya D; Ozutsumi T; Tsuji Y; Fujinaga Y; Kitagawa K; Furukawa M; Sato S; Sawada Y; Nishimura N; Takaya H; Okura Y; Seki K; Kawaratani H; Moriya K; Noguchi R; Asada K; Akahane T; Mitoro A; Yoshiji H Indian J Gastroenterol; 2022 Apr; 41(2):169-180. PubMed ID: 35279807 [TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia. Yoshida T; Tabony AM; Galvez S; Mitch WE; Higashi Y; Sukhanov S; Delafontaine P Int J Biochem Cell Biol; 2013 Oct; 45(10):2322-32. PubMed ID: 23769949 [TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. Namisaki T; Noguchi R; Moriya K; Kitade M; Aihara Y; Douhara A; Nishimura N; Takeda K; Okura Y; Kawaratani H; Takaya H; Seki K; Yoshiji H J Gastroenterol; 2016 Feb; 51(2):162-72. PubMed ID: 26190501 [TBL] [Abstract][Full Text] [Related]
10. Magnoliae Cortex Alleviates Muscle Wasting by Modulating M2 Macrophages in a Cisplatin-Induced Sarcopenia Mouse Model. Hong M; Han IH; Choi I; Cha N; Kim W; Kim SK; Bae H Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804803 [TBL] [Abstract][Full Text] [Related]
11. Skeletal muscle atrophy is exacerbated by steatotic and fibrotic liver-derived TNF-α in senescence-accelerated mice. Shirakami Y; Kato J; Maeda T; Ideta T; Imai K; Sakai H; Shiraki M; Shimizu M J Gastroenterol Hepatol; 2023 May; 38(5):800-808. PubMed ID: 36890117 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin-(1-7) attenuates disuse skeletal muscle atrophy in mice via its receptor, Mas. Morales MG; Abrigo J; Acuña MJ; Santos RA; Bader M; Brandan E; Simon F; Olguin H; Cabrera D; Cabello-Verrugio C Dis Model Mech; 2016 Apr; 9(4):441-9. PubMed ID: 26851244 [TBL] [Abstract][Full Text] [Related]
13. Yang L; Jiang X; Fu S; Tan J; Dian W; Zhou Y Discov Med; 2024 Feb; 36(181):402-414. PubMed ID: 38409845 [TBL] [Abstract][Full Text] [Related]
14. IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Yoshida T; Semprun-Prieto L; Sukhanov S; Delafontaine P Am J Physiol Heart Circ Physiol; 2010 May; 298(5):H1565-70. PubMed ID: 20228261 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin II inhibition: a potential treatment to slow the progression of sarcopenia. Kingsley J; Torimoto K; Hashimoto T; Eguchi S Clin Sci (Lond); 2021 Nov; 135(21):2503-2520. PubMed ID: 34751393 [TBL] [Abstract][Full Text] [Related]
16. Sarcopenia in the Cirrhotic Patient: Current Knowledge and Future Directions. Warner Ii ER; Satapathy SK J Clin Exp Hepatol; 2023; 13(1):162-177. PubMed ID: 36647414 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467 [TBL] [Abstract][Full Text] [Related]
18. SIRT1-dependent mechanisms and effects of resveratrol for amelioration of muscle wasting in NASH mice. Liu CW; Huang CC; Hsu CF; Li TH; Tsai YL; Lin MW; Tsai HC; Huang SF; Yang YY; Hsieh YC; Lee TY; Tsai CY; Huang YH; Hou MC; Lin HC BMJ Open Gastroenterol; 2020 May; 7(1):. PubMed ID: 32371503 [TBL] [Abstract][Full Text] [Related]
19. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Yoshida T; Delafontaine P Cells; 2020 Aug; 9(9):. PubMed ID: 32858949 [TBL] [Abstract][Full Text] [Related]